Novation Signs a Spinal Implant Agreement
Over the past several years, the spinal market has been one of the most attractive segments in orthopedics because of its high growth rates and relative lack of price pressure. But the recent signing of an agreement between spinal market leader Medtronic Sofamor Danek and Novation Inc. suggests the spinal market's high-flying days may be over.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.